title: Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus.
abstract: BACKGROUND
  The success of treatment of chronic hepatitis C (CHC) with pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV) is affected by several host, viral, and treatment factors. This study was designed to describe the association of interleukin (IL) 28B genotypes for rs12979860 with sustained virologic response (SVR) in patients with genotype 1 CHC infection treated with PEG-IFN α-2 and RBV.
  
  
  METHODS
  Interleukin-28B genotype in 100 studied patients was detected by tagman real-time polymerase chain reaction. Before treatment blood samples were obtained, then patients were treated for 48-week with a combination therapy using of the PEG-IFN α-2 and RBV. SVR evaluated 6 months after stopping therapy, and was defined as undetectable plasma hepatitis C virus-RNA.
  
  
  RESULTS
  Among studied patients, 65% were IL-28B CT, 27% CC, and 8% TT. In all studied patients, SVR was 58.3%, relapse 15.6%, and null virological response 26.1%. SVR rates were 76.9% in IL-28B-CC, 56.4% in IL-28B-CT, and 12.5% in IL-28B-TT patients. Relapse rates were 7.7% in IL-28B-CC, 12.9% in IL-28B-CT, and 62.5% in IL-28B-TT patients. There was a significant difference between response to treatment in patients IL-28B-CC, CT, and TT (P = 0.003). IL-28B genotype CC, (odds ratio = 0.053, 95% confidence interval; 0.005-0.54, P = 0.03), was the independent predicting factor.
  
  
  CONCLUSIONS
  Interleukin-28B was an important predictor of CHC treatment outcome with Peg-IFN-α and RBV. IL-28B-CC seems to be more important than IL-28B-CT/TT in predicting positive treatment response.
authors: Department of Gastroenterology, Isfahan Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors: Hamid
authors: H
authors: Kalantari
authors: Department of Gastroenterology, Isfahan Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors: Tahmine
authors: T
authors: Tavakoli
authors: Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors: Bahram
authors: B
authors: Bagherpour
authors: Department of Pharmacology and Toxicology, Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors: Shahram
authors: S
authors: Honarmand
keywords: Chronic hepatitis C; interleukin-28B; pegylated interferon-α; ribavirin
references: Liver Transpl. 2003 Nov;9(11):S10-3
references: 14586889
references: Aliment Pharmacol Ther. 2012 Jul;36(2):104-14
references: 22612303
references: Gastroenterology. 2010 Jul;139(1):120-9.e18
references: 20399780
references: J Viral Hepat. 2011 Jul;18(7):e325-31
references: 21692944
references: J Gastroenterol. 2006 Jan;41(1):17-27
references: 16501853
references: J Hepatol. 2011 Sep;55(3):692-701
references: 21440591
references: Ann Intern Med. 2004 Mar 2;140(5):346-55
references: 14996676
references: J Med Virol. 2011 Jul;83(7):1203-11
references: 21567424
references: Int J Med Sci. 2006;3(2):47-52
references: 16614742
references: Korean J Hepatol. 2008 Mar;14 (1):46-57
references: 18367857
references: Gastroenterology. 2010 Dec;139(6):1865-76
references: 20950615
references: Clin Gastroenterol Hepatol. 2011 Apr;9(4):344-350.e2
references: 20728570
references: Nat Genet. 2009 Oct;41(10):1100-4
references: 19749758
references: Korean J Hepatol. 2008 Sep;14 (3):318-30
references: 18815455
references: Lancet. 2001 Sep 22;358(9286):958-65
references: 11583749
references: Hepat Mon. 2012 Dec;12(12):e8387
references: 23550102
references: World J Gastroenterol. 2011 Jan 28;17 (4):419-32
references: 21274371
references: World J Gastroenterol. 2007 May 7;13(17):2436-41
references: 17552026
references: Clin Mol Hepatol. 2012 Dec;18(4):360-7
references: 23323251
references: Liver Int. 2009 Mar;29 Suppl 2:3-12
references: 19187068
references: Nat Genet. 2009 Oct;41(10):1105-9
references: 19749757
references: Int J Infect Dis. 2010 Sep;14 Suppl 3:e113-6
references: 20362479
references: Hepat Mon. 2011 Dec;11(12):975-9
references: 22368681
references: Hepat Mon. 2012 Sep;12(9):e6151
references: 23087759
references: Clin Infect Dis. 2008 Nov 15;47(10 ):1260-9
references: 18834319
references: Semin Liver Dis. 2004;24 Suppl 2:47-54
references: 15346246
references: Microbes Infect. 2002 Oct;4(12):1219-25
references: 12467763
references: Transl Res. 2007 Aug;150(2):116-21
references: 17656331
references: N Engl J Med. 2002 Sep 26;347(13):975-82
references: 12324553
references: Virol J. 2010 Nov 01;7:296
references: 21040548
references: Nature. 2009 Sep 17;461(7262):399-401
references: 19684573
references: World J Gastroenterol. 2007 Sep 28;13(36):4839-47
references: 17828815
references: J Gastrointestin Liver Dis. 2007 Mar;16(1):23-9
references: 17410285